Drug therapy in reproductive endocrinology:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
London [u.a.]
Arnold
1996
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XVIII, 382 S. |
| ISBN: | 0340613858 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV010652653 | ||
| 003 | DE-604 | ||
| 005 | 20030924 | ||
| 007 | t | ||
| 008 | 960308s1996 |||| 00||| engod | ||
| 020 | |a 0340613858 |9 0-340-61385-8 | ||
| 035 | |a (OCoLC)34479347 | ||
| 035 | |a (DE-599)BVBBV010652653 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-91 | ||
| 082 | 0 | |a 616.69061 |2 20 | |
| 082 | 0 | |a 616.4061 |2 20 | |
| 084 | |a YM 3115 |0 (DE-625)153831:12921 |2 rvk | ||
| 084 | |a MED 566f |2 stub | ||
| 245 | 1 | 0 | |a Drug therapy in reproductive endocrinology |c ed. by Jean Ginsburg |
| 264 | 1 | |a London [u.a.] |b Arnold |c 1996 | |
| 300 | |a XVIII, 382 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Endocrine System Diseases |x drug therapy | |
| 650 | 4 | |a Endocrine glands |x Diseases |x Hormone therapy | |
| 650 | 4 | |a Fertility Agents |x therapeutic use | |
| 650 | 4 | |a Human reproduction |x Endocrine aspects | |
| 650 | 4 | |a Infertility |x drug therapy | |
| 650 | 4 | |a Reproduction |x physiology | |
| 650 | 0 | 7 | |a Gynäkologische Endokrinologie |0 (DE-588)4140952-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Endokrinologie |0 (DE-588)4014663-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Reproduktionsmedizin |0 (DE-588)4197011-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Reproduktionsmedizin |0 (DE-588)4197011-1 |D s |
| 689 | 0 | 1 | |a Endokrinologie |0 (DE-588)4014663-7 |D s |
| 689 | 0 | 2 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Gynäkologische Endokrinologie |0 (DE-588)4140952-8 |D s |
| 689 | 1 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Ginsburg, Jean |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007109678&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-007109678 | ||
Datensatz im Suchindex
| _version_ | 1804125130540974080 |
|---|---|
| adam_text | DRUG THERAPY IN REPRODUCTIVE ENDOCRINOLOGY EDITED BY JEAN GINSBURG MA,
DM, FRCP CONSULTANT ENDOCRINOLOGIST, JOINT UNIVERSITY DEPARTMENT OF
MEDICINE, ROYAL FREE HOSPITAL SCHOOL OF MEDICINE AND UNIVERSITY COLLEGE
LONDON, UK WITH THE EDITORIAL ASSISTANCE OF GORDANA M PRELEVIC MD, DSC,
FRCP PROFESSOR OF MEDICINE, BELGRADE UNIVERSITY SCHOOL OF MEDICINE,
BELGRADE, YUGOSLAVIA AND CLINICAL LECTURER, UNIVERSITY DEPARTMENT OF
MEDICINE, UNIVERSITY COLLEGE LONDON MEDICAL SCHOOL, THE MIDDLESEX
HOSPITAL, LONDON, UK A MEMBER OF THE HODDER HEADLINE GROUP LONDON *
SYDNEY * AUCKLAND CO-PUBLISHED IN THE USA BY OXFORD UNIVERSITY PRESS,
INC., NEW YORK CONTENTS LIST OF CONTRIBUTORS XII FOREWORD XIV PREFACE XV
ABBREVIATIONS XVI 1 PHARMACOLOGICAL PRINCIPLES OF DRUG ACTION IAN M
JAMES 1 1. INTRODUCTION 1 2. DRUG EFFECTS MEDIATED VIA RECEPTORS 1 2. 7
DIRECT REGULATION OF IONIC PERMEABILITY 2 2.2 INDIRECT EFFECTS BY
C-PROTEIN COUPLING AND TRANSMISSION VIA SECOND MESSENGERS OR ION
CHANNELS 2 2.3 TYROSINE-KINASE-LINKED RECEPTORS 2 2.4 NUCLEAR AND
CYTOSOLIC HORMONE RECEPTORS 3 2.5 EFFECT DUE TO INDIRECT ACTIONS 4 2.6
REGULATION OF RECEPTORS 5 3. DRUG EFFECTS NOT MEDIATED BY RECEPTORS 5 4.
QUANTITATION OF DRUG RECEPTOR INTERACTIONS 5 5. RELATIONSHIP BETWEEN THE
DOSE OF DRUG AND THE RESPONSE IN THE PATIENT 7 5. 7 PHARMACOKINETICS 8
5.2 WEAK ELECTROLYTES AND INFLUENCE OF PH 8 5.3 FACTORS THAT MODIFY
ABSORPTION 9 5.4 DISTRIBUTION OF DRUGS 11 5.5 PLACENTAL TRANSFER 11 5.6
METABOLISM OR BIOTRANSFORMATION OF DRUGS 12 5.7 PHARMACOKINETICS AND
CLEARANCE 14 5.8 RULES GOVERNING CONSTANT INFUSION OR CONSTANT DOSING 1
7 6. PHARMACOKINETIC CONSIDERATIONS FOR SPECIAL SITUATIONS - BASIC
PRINCIPLES 18 6.7 PREGNANCY 18 6.2 LACTATION 18 6.3 PRESCRIBING FOR THE
ELDERLY 19 2 DISORDERS OF PUBERTY ASSUNTA ALBANESE AND RICHARD STANHOPE
21 1. INTRODUCTION 21 2. PHYSIOLOGY OF GONADOTROPHIN SECRETION AND
SEXUAL MATURATION 22 3. CAUSES OF PREMATURE SEXUAL MATURATION 25 3. 7
PRECOCIOUS PUBERTY 25 3.2 VARIANTS OF PRECOCIOUS PUBERTY 26 IV CONTENTS
4. INVESTIGATION OF PREMATURE SEXUAL MATURATION 27 4.1 CLINICAL
ASSESSMENT 27 4.2 DIAGNOSTIC TESTS 28 5. TREATMENT OF PREMATURE SEXUAL
MATURATION 29 6. CAUSES OF DELAYED AND ARRESTED PUBERTY 30 7.
INVESTIGATION OF DELAYED PUBERTY 32 7.1 CLINICAL ASSESSMENT 32 7.2
DIAGNOSTIC TESTS 32 8. TREATMENT OF DELAYED PUBERTY 33 CONCLUSION 34 3
AMENORRHOEA AND OLIGOMENORRHOEA JEAN GINSBURG AND GORDANA M PRELEVIC 36
1. DEFINITION 36 2. CAUSES 37 2.1 HYPOTHALAMIC DISORDERS 38 2.2
PITUITARY DISORDERS 39 2.3 THYROID DISEASE 40 2.4 DISORDERS OF THE
ADRENAL GLAND 40 2.5 GONADAL DISORDERS 40 2.6 DISORDERS OF THE GENITAL
TRACT 42 3. INVESTIGATION 42 3.1 CLINICAL ASSESSMENT 43 3.2 PELVIC
ULTRASOUND SCANNING 44 3.3 HORMONAL TESTS 45 3.4 OTHER INVESTIGATIONS 46
4. TREATMENT 48 4.1 GENERAL PRINCIPLES 48 4.2 INDUCTION OF OVULATION 50
4.3 PREVENTION OF LONG-TERM COMPLICATIONS OF HYPO-OESTROGENISM 50 4.4
PREVENTION OF ENDOMETRIAL HYPERPLASIA 5 1 4 HYPERPROLACTINAEMIA STEVEN
SOULE AND HOWARD S JACOBS 52 1. INTRODUCTION 52 2. PHYSIOLOGY OF
DOPAMINE IN THE CNS 53 3. CAUSES OF HYPERPROLACTINAEMIA 54 3.1
PHYSIOLOGICAL 54 3.2 DRUGS 55 3.3 PATHOLOGICAL 55 4. DIAGNOSTIC
EVALUATION 56 5. TREATMENT 56 5.7 GENERAL OVERVIEW - INDICATIONS FOR
TREATMENT 56 5.2 BROMOCRIPTINE 59 5.3 QUINAGOLIDE 62 5.4 CABERGOLINE 63
5.5 OTHER AGENTS 64 6. PREGNANCY AND HYPERPROLACTINAEMIA 64 SUMMARY 65
CONTENTS V 5 HIRSUTISM AND THE POLYCYSTIC OVARY SYNDROME GORDANA M
PRELEVIC 67 1. DEFINITION OF THE CLINICAL PROBLEM 67 7.7 HIRSUTISM 67
1.2 THE POLYCYSTIC OVARY SYNDROME 68 2. CAUSES OF HIRSUTISM 68 2.1
CIRCULATING ANDROGENS IN WOMEN AND THEIR ORIGIN 68 2.2 THE EFFECTS OF
ANDROGENS ON THE PILOSEBACEOUS UNIT 70 2.3 ADRENAL CAUSES OF HIRSUTISM
71 2.4 OVARIAN CAUSES OF HIRSUTISM 71 2.5 IDIOPATHIC HIRSUTISM 72 2.6
LATROGENIC CAUSES OF HIRSUTISM 72 3. DIAGNOSTIC TESTS 72 3. 7 CLINICAL
ASSESSMENT OF WOMEN WITH HIRSUTISM 72 3.2 ASSESSMENT OF ORIGIN OF
ANDROGENS 73 4. TREATMENT 75 ! 4.7 PRINCIPLES OF MEDICAL MANAGEMENT OF
HIRSUTISM 75 4.2 TREATMENT OPTIONS FOR WOMEN WITH POLYCYSTIC OVARIES 77
4.3 MEDICAL MANAGEMENT OF HIRSUTISM 78 6 INDUCTION OF OVULATION PAUL
HARDIMAN AND JEAN GINSBURG 86 1. WHAT IS INFERTILITY? 86 2. CAUSES OF
INFERTILITY 86 3. INVESTIGATION OF THE INFERTILE COUPLE 87 4. INDUCTION
OF OVULATION 90 4.1 ANTI-OESTROGEN THERAPY 90 4.2 GONADOTROPHIN THERAPY
92 4.3 PULSATILE GONADOTROPHIN RELEASING HORMONE 99 4.4 OVARIAN
STIMULATION IN ASSISTED REPRODUCTION PROGRAMMES 101 5. COMPLICATIONS OF
OVULATION INDUCTION THERAPY 103 5.7 EARLY COMPLICATIONS 103 5.2 LATE
COMPLICATIONS 104 SUMMARY 104 7 PREMENSTRUAL SYNDROME IMAD E H ABUKHALIL
AND P M SHAUGHN O BRIEN 107 1. HISTORY 107 2. DEFINITION 108 2.1
PHYSIOLOGICAL PREMENSTRUAL SYNDROME 108 2.2 PRIMARY PREMENSTRUAL
SYNDROME 108 2.3 SECONDARY PREMENSTRUAL SYNDROME 108 3. PRESENTATION 108
3.1 PSYCHOLOGICAL SYMPTOMS 108 3.2 PHYSICAL SYMPTOMS 109 3.3 THE
PREMENSTRUAL SYNDROME AND BREAST SYMPTOMS 109 4. AETIOLOGY 109 5.
DIAGNOSIS 110 6. TREATMENT 110 6.7 NON-PHARMACEUTICAL THERAPY 110 6.2
NON-HORMONAL THERAPY 112 VI CONTENTS 6.3 HORMONAL THERAPY 6.4 SURGERY 7.
CHOICE OF TREATMENT SUMMARY 8 DYSMENORRHOEA MARY ANN LUMSDEN AND GILL
IRVINE 1. DEFINITION OF CLINICAL PROBLEM 2. AETIOLOGY 3. INVESTIGATION
4. TREATMENT 4.1 NON-STEROIDAI ANTI-INFLAMMAORY DRUGS 4.2 COMBINED
OESTROGEN/PROGESTOGEN ORAL CONTRACEPTIVE 4.3 GESTOGEN THERAPY 4.4
DANAZOL 4.5 GONADOTROPHIN RELEASING HORMONE AGONISTS ** 5. ALTERNATIVE
THERAPY 5.7 SECONDARY DYSMENORRHOEA 5.2 FUTURE DEVELOPMENTS SUMMARY 112
113 113 115 116 116 116 118 119 119 120 120 121 121 122 122 122 122 9
DYSFUNCTIONAL UTERINE BLEEDING SHEILA L B DUNCAN 12 4 1. DEFINITION OF
THE CLINICAL PROBLEM 124 7.7 NATURAL HISTORY OF MENSTRUAL CYCLE 124 2.
CAUSES OF DYSFUNCTIONAL UTERINE BLEEDING 125 2.1 ANOVUIATORY CYCLES 125
2.2 OVULATORY CYCLES 125 2.3 ENDOMETRIUM 126 3. DIAGNOSTIC TESTS 128 3.
7 OBJECTIVE ESTIMATION 129 3.2 INVASIVE TESTS 129 4. TREATMENT 130 4.1
ASSESSMENT OF DRUG THERAPY 130 4.2 DRUG THERAPY 131 4.3 CHOICE OF
TREATMENT 135 SUMMARY 136 10 ENDOMETRIOSIS IAN COOKE 138 1. DEFINITION
OF THE CLINICAL PROBLEM 138 7.7 REASON FOR REFERRAL 138 1.2 CLINICAL
DISEASE 139 2. CAUSES 139 2.1 MECHANICAL 139 2.2 OESTROGEN DEPENDENCE
139 2.3 COELOMIC METAPLASIA 139 2.4 GENETIC AND IMMUNOLOGICAL 140 3.
DIAGNOSTIC TESTS 140 3.1 CLINICAL EXAMINATION 140 3.2 ULTRASOUND 140 3.3
LAPAROSCOPY 141 CONTENTS VI I 3.4 BIOPSY 141 3.5 CARCINOMA ANTIGEN 125,
PLACENTA! PROTEIN 14 141 3.6 MAGNETIC RESONANCE IMAGING 141 3.7 OTHER
TESTS 141 4. THERAPEUTIC APPROACHES 142 4.1 GENERAL 142 4.2 TREATMENT AT
TIME OF INITIAL LAPAROSCOPY 142 4.3 MEDICAL TREATMENT 142 4.4 MEDICAL
TREATMENT PRE-SURGERY 146 4.5 MEDICAL TREATMENT POST-SURGERY 146 4.6 IN
VITRO FERTILISATION 146 4.7 OOPHORECTOMY AND CLIMACTERIC THERAPY 147
SUMMARY 147 11 UTERINE FIBROIDS CHRISTINE P WEST 149 1. CLINICAL PROBLEM
149 2. PATHOGENESIS 149 3. DIAGNOSTIC TESTS 150 4. TREATMENT 150 4.1
GENERAL PRINCIPLES 150 4.2 SURGERY 151 4.3 DRUG THERAPY 151 SUMMARY 157
12 ENDOCRINE CONTRACEPTION JOHN NEWTON, GILLIAN E ROBINSON AND MASOUD
AFNAN 158 1. COMBINED ORAL CONTRACEPTIVES 158 7.7 HISTORY 158 1.2
MECHANISM OF CONTRACEPTIVE EFFECT 159 1.3 INDICATIONS 160 1.4 EFFICACY
160 1.5 MODE OF ADMINISTRATION 16 1 1.6 NON-CONTRACEPTIVE HEALTH
BENEFITS 161 1.7 HEALTH RISKS 162 1.8 METABOLIC EFFECTS 164 1.9 EFFECT
ON PREGNANCY 166 7.70 SUMMARY 166 2. PROGESTOGEN-ONLY ORAL
CONTRACEPTIVES 166 2.1 MODE OF ACTION 166 2.2 INDICATIONS 167 2.3 METHOD
167 2.4 EFFICACY 168 2.5 SIDE EFFECTS 168 2.6 NON-CONTRACEPTIVE BENEFITS
168 2.7 SUMMARY 169 3. PROGESTOGEN-ONLY INJECTABLE CONTRACEPTIVE
PREPARATIONS 169 3.1 PROGESTOGEN-ONLY METHODS 169 4. PROGESTOGEN-ONLY
IMPLANTS 171 4.1 NORPLANT-6 172 VIII CONTENTS 4.2 4.3 NORPLANT 2
IMPLANON 5. LEVONORGESTREL-RELEASING INTRAUTERINE DEVICE 5.1 5.2 5.3 5.4
5.5 5.6 METHOD INDICATIONS CON TRAINDICA TIONS EFFICACY SIDE EFFECTS
SUMMARY 6. COMBINED INJECTABLE CONTRACEPTIVE PREPARATIONS 6.1 6.2 6.3
6.4 6.5 6.6 METHOD USE INDICATIONS CONTRAINDICATIONS EFFICACY SIDE
EFFECTS 7. POSTCOITAL CONTRACEPTION 7.1 7.2 PC4 MIFEPRISTONE CONCLUSIONS
173 173 174 174 174 174 174 175 175 175 175 176 176 176 177 177 177 177
178 178 13 DISORDERS OF THE BREAST 180 (I) BENIGN BREAST DISEASE REGINE
SITRUK-WARE 180 1. INTRODUCTION 180 2. DEFINITION OF THE CLINICAL
PROBLEM 180 2.1 REASONS FOR REFERRAL TO BREAST CONSULTANT 180 2.2 BENIGN
BREAST DISEASE 181 2.3 BREAST CANCER: DIFFERENTIAL DIAGNOSIS 184 3.
CAUSES OF BENIGN BREAST DISEASE 184 3.1 HORMONE DEPENDENCE OF THE HUMAN
BREAST: CONTROVERSIES 184 3.2 ENDOCRINE CAUSES OF BENIGN BREAST DISEASE
186 4. DIAGNOSTIC TESTS 187 4.1 MAMMOGRAPHY 187 4.2 XEROGRAPHY 188 4.3
THERMOGRAPHY 188 4.4 ULTRASONOGRAPHY 188 4.5 NEEDLE BIOPSY 189 5.
THERAPEUTIC APPROACHES 189 5.7 RATIONALE FOR TREATMENT 18 9 5.2
THERAPEUTIC OPTIONS 190 SUMMARY 192 (II) MALIGNANT BREAST DISEASE P
NICHOLAS PLOWMAN 194 1. INTRODUCTION 194 2. OESTROGENS, ANDROGENS AND
GLUCOCORTICOIDS 195 3. TAMOXIFEN 195 4. MEDICAL ADRENALECTOMY 197 4.1
AMINOGLUTETHIMIDE 197 4.2 4-HYDROXYANDROSTENEDIONE 198 5. PROGESTOGENS
198 CONTENTS IX 14 HORMONAL MANAGEMENT OF WOMEN WITH REPRODUCTIVE TRACT
MALIGNANCIES WENDY M N REID AND ALLAN B MACLEAN 200 1. INTRODUCTION 200
2. THE OVARY 200 2.1 PROGESTOGENS 201 2.2 ANTI-OESTROGENS 201 2.3
GONADOTROPHIN RELEASING HORMONE AGONISTS 202 2.4 OESTROGENS 202 3. THE
ENDOMETRIUM 202 3.1 PROGESTOGENS 202 3.2 ANTI-OESTROGENS 203 3.3
GONADOTROPHIN RELEASING HORMONE AGONISTS 203 4. UTERINE SARCOMA 203 5.
TROPHOBLASTIC DISEASE 203 6. CERVICAL CARCINOMA 204 7. VAGINAL CARCINOMA
205 8. VULVAL CARCINOMA 205 15 THE MENOPAUSE STANLEY OKOLO AND JEAN
GINSBURG 207 1. INTRODUCTION AND DEFINITION OF TERMS 207 2.
PATHOPHYSIOLOGY OF THE MENOPAUSE 208 2.1 OVARIAN FOLLICULAR DEPLETION
208 2.2 FOLLICULAR SENSITIVITY AND CIRCULATING HORMONES 209 3. CLINICAL
MANIFESTATIONS 209 3.1 SYMPTOMS 209 3.2 LONG-TERM EFFECTS 210 4.
INVESTIGATION AND DIAGNOSIS 210 4.1 BLOOD TESTS 211 4.2 SCREENING FOR
GENITAL MALIGNANCY OR OSTEOPOROSIS 211 4.3 DIFFERENTIAL DIAGNOSIS 211 5.
MANAGEMENT 212 5.1 INDICATIONS FOR MENOPAUSAL THERAPY 212 5.2. OESTROGEN
THERAPY 212 5.3 PROGESTOGENS AND COMBINED OESTROGEN-PROGESTOGEN THERAPY
2 1 7 5.4 TIBOLONE 218 5.5 OTHER HORMONAL THERAPY 219 5.6 NON-HORMONAL
THERAPY 219 5.7 MONITORING OF MENOPAUSAL THERAPY 220 CONCLUSION 221 16
POST-MENOPAUSAL OSTEOPOROSIS WASSIF S WASSIF AND RICHARD S FINK 223 1.
INTRODUCTION 223 2. PATHOPHYSIOLOGY 224 2.1 BONE CELLS 224 2.2 BONE
MATRIX 225 3. PEAK BONE MASS 226 4. BONE STRUCTURE 226 X CONTENTS 4.1
CORTICAL BONE LOSS 227 4.2 TRABECULAR BONE LOSS 227 5. RISK FACTORS FOR
OSTEOPOROSIS 227 6. CLINICAL FEATURES 228 7. THE LABORATORY
INVESTIGATION OF OSTEOPOROSIS 229 7.7 ROUTINE LABORATORY TESTS 229 7.2
TESTS OF BONE RESORPTION 230 7.3 TESTS OF BONE FORMATION 231 8.
MEASUREMENT OF BONE MASS 232 9. PREVENTION 233 9.1 THE TEENAGE YEARS 233
9.2 THE ADULT YEARS 233 9.3 POST-MENOPAUSAL YEARS 234 10. TREATMENT OF
ESTABLISHED OSTEOPOROSIS WITH OESTROGENS 235 70.7 INDICATIONS 235 70.2
GENERAL PRINCIPLES OF TREATMENT 236 70.3 PATIENT MONITORING 238 70.4
ADJUNCTIVE THERAPY 238 11. INHIBITION OF BONE RESORPTION BY
NON-OESTROGENIC THERAPY 238 7 7.7 TIBOLONE 238 7 7.2 CALCITONIN 239 7
7.3 BIPHOSPHONATES 239 7 7.4 CALCIUM & VITAMIN D 240 12 NON-OESTROGENIC
COMPOUNDS STIMULATING BONE FORMATION 240 72.7 SODIUM FLUORIDE 240 72.2
ANABOLIC STEROIDS 241 72.3 OTHER AGENTS WHICH MAY HAVE A ROLE IN THE
FUTURE 241 17 MALE HYPOGONADISM, INFERTILITY AND IMPOTENCE RICHARD
QUINTON AND PIERRE-M G BOULOUX 242 1. INTRODUCTION 242 7.7 PHYSIOLOGY OF
THE HYPOTHALAMO-PITUITARY-TESTICULAR AXIS 242 2. HYPOGONADISM 243 2.7
CLINICAL FEATURES OF ANDROGEN DEFICIENCY IN THE MALE 243 2.2
CLASSIFICATION OF ANDROGEN DEFICIENCY 244 2.3 HYPOGONADOTROPHIC
HYPOGONADISM 244 2.4 HYPERPROLACTINAEMIA 245 2.5 PRIMARY TESTICULAR
FAILURE 246 2.6 SYSTEMIC DISEASE 247 2.7 DISORDERS OF ANDROGEN
RESISTANCE AND BIOSYNTHESIS 247 2.8 DRUGS AND TOXINS 247 2.9 TREATMENT
OF HYPOGONADISM 249 3. INFERTILITY 250 3.7 DISORDERS OF TESTICULAR
THERMOREGULATION 251 3.2 ENVIRONMENTAL AGENTS 251 3.3 CONGENITAL DEFECTS
252 3.4 SEXUAL AND EJACULATORY DYSFUNCTION 252 3.5 SPERM AUTO-IMMUNITY
252 3.6 INFECTION OF THE MALE GENITOURINARY TRACT 253 CONTENTS XI 3.7
IDIOPATHIC DEFECTS OF SPERM MOTILITY AND MORPHOLOGY 253 3.8 MANAGEMENT
OF THE INFERTILE MALE 253 4. MALE IMPOTENCE 254 4.1 PSYCHOGENIC
IMPOTENCE 254 4.2 ORGANIC IMPOTENCE 255 4.3 MANAGEMENT OF ORGANIC
IMPOTENCE 256 CONCLUSION 257 18 PROSTATIC HYPERTROPHY AND CANCER ROBERT
MORGAN 259 1. INTRODUCTION 259 2. CAUSES OF PROSTATIC ENLARGEMENT 260 3.
DIAGNOSTIC TESTS 260 4. TREATMENT 261 4.1 TREATMENT OF BENIGN
HYPERTROPHY 261 4.2 TREATMENT OF PROSTATIC MALIGNANCY 262 19
PHARMACOPOEIA JEAN GINSBURG AND GORDANA M PRELEVIC 266 INDEX 374
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV010652653 |
| classification_rvk | YM 3115 |
| classification_tum | MED 566f |
| ctrlnum | (OCoLC)34479347 (DE-599)BVBBV010652653 |
| dewey-full | 616.69061 616.4061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.69061 616.4061 |
| dewey-search | 616.69061 616.4061 |
| dewey-sort | 3616.69061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02019nam a2200517 c 4500</leader><controlfield tag="001">BV010652653</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20030924 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">960308s1996 |||| 00||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0340613858</subfield><subfield code="9">0-340-61385-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)34479347</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV010652653</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-91</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.69061</subfield><subfield code="2">20</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.4061</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YM 3115</subfield><subfield code="0">(DE-625)153831:12921</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MED 566f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug therapy in reproductive endocrinology</subfield><subfield code="c">ed. by Jean Ginsburg</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London [u.a.]</subfield><subfield code="b">Arnold</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVIII, 382 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endocrine System Diseases</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endocrine glands</subfield><subfield code="x">Diseases</subfield><subfield code="x">Hormone therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fertility Agents</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Human reproduction</subfield><subfield code="x">Endocrine aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Infertility</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Reproduction</subfield><subfield code="x">physiology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gynäkologische Endokrinologie</subfield><subfield code="0">(DE-588)4140952-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Endokrinologie</subfield><subfield code="0">(DE-588)4014663-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Reproduktionsmedizin</subfield><subfield code="0">(DE-588)4197011-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Reproduktionsmedizin</subfield><subfield code="0">(DE-588)4197011-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Endokrinologie</subfield><subfield code="0">(DE-588)4014663-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Gynäkologische Endokrinologie</subfield><subfield code="0">(DE-588)4140952-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ginsburg, Jean</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007109678&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-007109678</subfield></datafield></record></collection> |
| id | DE-604.BV010652653 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T17:56:40Z |
| institution | BVB |
| isbn | 0340613858 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-007109678 |
| oclc_num | 34479347 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-91 DE-BY-TUM |
| owner_facet | DE-355 DE-BY-UBR DE-91 DE-BY-TUM |
| physical | XVIII, 382 S. |
| publishDate | 1996 |
| publishDateSearch | 1996 |
| publishDateSort | 1996 |
| publisher | Arnold |
| record_format | marc |
| spelling | Drug therapy in reproductive endocrinology ed. by Jean Ginsburg London [u.a.] Arnold 1996 XVIII, 382 S. txt rdacontent n rdamedia nc rdacarrier Endocrine System Diseases drug therapy Endocrine glands Diseases Hormone therapy Fertility Agents therapeutic use Human reproduction Endocrine aspects Infertility drug therapy Reproduction physiology Gynäkologische Endokrinologie (DE-588)4140952-8 gnd rswk-swf Endokrinologie (DE-588)4014663-7 gnd rswk-swf Reproduktionsmedizin (DE-588)4197011-1 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Reproduktionsmedizin (DE-588)4197011-1 s Endokrinologie (DE-588)4014663-7 s Pharmakotherapie (DE-588)4076066-2 s DE-604 Gynäkologische Endokrinologie (DE-588)4140952-8 s Ginsburg, Jean Sonstige oth GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007109678&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Drug therapy in reproductive endocrinology Endocrine System Diseases drug therapy Endocrine glands Diseases Hormone therapy Fertility Agents therapeutic use Human reproduction Endocrine aspects Infertility drug therapy Reproduction physiology Gynäkologische Endokrinologie (DE-588)4140952-8 gnd Endokrinologie (DE-588)4014663-7 gnd Reproduktionsmedizin (DE-588)4197011-1 gnd Pharmakotherapie (DE-588)4076066-2 gnd |
| subject_GND | (DE-588)4140952-8 (DE-588)4014663-7 (DE-588)4197011-1 (DE-588)4076066-2 |
| title | Drug therapy in reproductive endocrinology |
| title_auth | Drug therapy in reproductive endocrinology |
| title_exact_search | Drug therapy in reproductive endocrinology |
| title_full | Drug therapy in reproductive endocrinology ed. by Jean Ginsburg |
| title_fullStr | Drug therapy in reproductive endocrinology ed. by Jean Ginsburg |
| title_full_unstemmed | Drug therapy in reproductive endocrinology ed. by Jean Ginsburg |
| title_short | Drug therapy in reproductive endocrinology |
| title_sort | drug therapy in reproductive endocrinology |
| topic | Endocrine System Diseases drug therapy Endocrine glands Diseases Hormone therapy Fertility Agents therapeutic use Human reproduction Endocrine aspects Infertility drug therapy Reproduction physiology Gynäkologische Endokrinologie (DE-588)4140952-8 gnd Endokrinologie (DE-588)4014663-7 gnd Reproduktionsmedizin (DE-588)4197011-1 gnd Pharmakotherapie (DE-588)4076066-2 gnd |
| topic_facet | Endocrine System Diseases drug therapy Endocrine glands Diseases Hormone therapy Fertility Agents therapeutic use Human reproduction Endocrine aspects Infertility drug therapy Reproduction physiology Gynäkologische Endokrinologie Endokrinologie Reproduktionsmedizin Pharmakotherapie |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007109678&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT ginsburgjean drugtherapyinreproductiveendocrinology |